Recent studies have demonstrated dose-dependent cytotoxicity against various cancer cell lines, with McEO reducing viability in prostate cancer cells (IC50: 100–400 μg/mL), activating caspase-3 and PARP cleavage, and impairing cell migration [19]. Here, PARP1 is linked to cancer.